X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Thermo Fisher Scientific Introduces Next Generation of Complementary Technologies for Forensic DNA Analysis

Yuvraj_pawp by Yuvraj_pawp
18th July 2017
in Asia, News

Forensic scientists who need to differentiate genetic profiles in forensic DNA mixtures, such as those commonly associated with crime scenes, now have access to a new next-generation sequencing (NGS) STR panel from Thermo Fisher Scientific. The combination of Applied Biosystems Precision ID GlobalFiler NGS STR Panel v2 and Converge Software 2.0 is designed to effectively retrieve more information from these mixed, degraded or limited DNA samples.

 

Forensic scientists have traditionally used capillary electrophoresis (CE) to analyze STR markers for genetic profile comparisons with known individuals from the FBI’s Combined DNA Index System (CODIS) database and other databases worldwide. However, complicating factors, such as DNA degradation, mixtures and/or insufficient starting material, prevent an estimated 30-40 percent of samples from offering conclusive results.


The new Precision ID GlobalFiler NGS STR Panel v2 is designed to work seamlessly with the Ion Chef System for automated library and template preparation and sequencing on the Ion S5 and Ion S5 XL Systems, which offer as little as two hour sequencing run times and 15 minutes of hands-on time. The panel targets CODIS expanded core loci, with additional multi-allelic STR markers, including Penta D and Penta E, as well as sex determination markers. This expanded marker set assists in mixture resolution for identifying multiple contributors in complex casework samples.


The new Converge NGS Analysis module is required to generate profiles from the Precision ID GlobalFiler NGS STR Panel v2. The HID STR genotyping functionality provides information on length-based STR allele call, sequence-based repeat motif, known SNPs in flanking regions, and isometric heterozygote (alleles of the same fragment length, but containing different repeat sequence) information. These additional sequence-based characteristics will deliver a wider allele range with an increased power of discrimination for individual identification. With an interface which is similar to Applied Biosystems GeneMapper ID-X software, forensic analysts can easily evaluate sequencing data using familiar Process Quality Values and flags, such as allele number (AN), off-ladder allele (OL), peak height ratio (PHR), below stochastic threshold (BST) and Control Concordance (CC).


“NGS now has the ability to transform forensic genetics by enabling the recovery of highly discriminating allelic profiles from challenging mixed or degraded samples,” said Claus Børsting, Ph.D., senior advisor at the Section of Forensic Genetics, Department of Forensic Medicine, University of Copenhagen, Denmark. “Our tests show full concordance with CE based methods, high sensitivity, and new possibilities for mixture interpretation. Under our ISO 17025 laboratory accreditation, we have used NGS in relationship case work since 2015. Currently, we are validating an ancestry panel to bring NGS on-line in crime case work.”


“Our customers need more access to genetic identification profiles from complex DNA samples, prompting the continued development of the Precision ID NGS System, additional panels and a more comprehensive data analysis pipeline.” said Rosy Lee, vice president and general manager of human identification at Thermo Fisher Scientific.


Additional information on the Precision ID NGS System with Converge software can be found here.
The Precision ID NGS System is for research, forensic or paternity use only; Not for use in diagnostic procedures.


About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com

 

Media Contact Information:

Mauricio Minotta, Thermo Fisher Scientific
+1 760 929 2456
mauricio.minotta@thermofisher.com

Tags: Middle East & South Asia
Previous Post

DelMar Pharmaceuticals Receives IRB Approval for Pivotal Phase 3 Clinical Trial of VAL-083

Next Post

PersonalMed Partners with Bergen’s Elevate Provider Network to Assist Compounding Pharmacies

Related Posts

Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
America Facing Heart Health Issues Since The Pandemic Began
News

America Facing Heart Health Issues Since The Pandemic Began

8th February 2022
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants
News

T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

7th February 2022
OLUMIANT® (baricitinib) 2-mg Tablets gets FDA approval to treat adult patients with moderately to severely active Rheumatoid Arthritis
Manufacturing

Lilly announces $1 billion investment in new manufacturing facility in North Carolina

7th February 2022
Recipharm supports FDA approval of Perrigos AB-rated generic product
News

Recipharm acquires GenIbet to bolster Biologics offering

7th February 2022
Next Post

PersonalMed Partners with Bergen’s Elevate Provider Network to Assist Compounding Pharmacies

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In